AstraZeneca

News

WCLC: Biomarker could guide Dato-DXd use in lung cancer

A biomarker could help identify patients with lung cancer who are most likely to benefit from treatment with AstraZeneca and Daiichi Sankyo's TROP2-directed drug datopotamab deruxtecan (Dat

News

AstraZeneca China HQ: at Shanghai Zhangjiang Hi-Tech Park

China detains AstraZeneca workers in data, imports probe

AstraZeneca has confirmed that some of its current and former employees have been taken into custody in China as part of an investigation into data privacy breaches and the import of unlice

News

Alnylam hails vutrisiran data, but investors seem sceptical

Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems t

News

AstraZeneca dismisses rumours of facility relocation to US

AstraZeneca has said it has "no idea" where rumours of a plan to relocate a planned facility in the UK to the US have come from, adding: "They do not seem to be based on facts."

News

J&J's Rybrevant okay challenges Tagrisso in first-line NSCLC

AstraZeneca's EGFR inhibitor Tagrisso has become the go-to therapy for EGFR-mutated non-small cell lung cancer (NSCLC), but now has competition from Johnson & Johnson's Rybrevant and La

News

EU starts review of Enhertu in HER2-ultra-low breast cancer

The EMA has started a review of AstraZeneca and Daiichi Sankyo's antibody-drug conjugate (ADC) that could see the drug being used in advanced breast cancer with even lower levels of the HER

WCLC: Biomarker could guide Dato-DXd use in lung cancer

China detains AstraZeneca workers in data, imports probe

Alnylam hails vutrisiran data, but investors seem sceptical

AstraZeneca dismisses rumours of facility relocation to US

J&J's Rybrevant okay challenges Tagrisso in first-line NSCLC

EU starts review of Enhertu in HER2-ultra-low breast cancer

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

AstraZeneca

Editor's Picks